Combination immunotherapy induces distinct T-cell repertoire responses when administered to patients with different malignancies.
Journal for immunotherapy of cancer
TCR Convergence in Individuals Treated With Immune Checkpoint Inhibition for Cancer.
Frontiers in immunology
Balancing the Checkpoint: Managing Colitis Associated with Dual Checkpoint Inhibitors and High-Dose Aspirin.
Digestive diseases and sciences
A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in ...
Dose limiting toxicity (DLT) is defined as protocol-defined adverse events that occur within 28 days following infusion of Neo-TCR-P1 administered as a single agent or in combination with nivolumab.
Study of MK-1454 Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Adva...
DLTs will be assessed during the first cycle (21 days) & are defined as: Grade (Gr) 4 nonhematologic toxicity; Gr 4 hematologic toxicity lasting ≥7 days, except thrombocytopenia, Gr 4 thrombocytopenia, Gr 3 thrombocytopenia (if as...
Treatment With Nivolumab and Ipilimumab or Nivolumab Alone According to the Percentage of Tumor...
The proportion of participants who show clinical benefit, defined as complete response (CR), partial response (PR), or stable disease (SD) for ≥ 6 months as best response by RECIST v1.1